EditorialProgression-free survival: Starting point or endpoint in advanced HCC trial design?
Section snippets
Conflict of interest
RSF has received consulting fees from AstraZaeneca, Bayer, Bristol Myers Squibb, Esiai, Exilixis, Eli Lilly, Novartis, Merck, Pfizer, Roche/Genentech.
Please refer to the accompanying ICMJE disclosure forms for further details.
References (13)
- et al.
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase III trial
Lancet
(2017) - et al.
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase III trial
Lancet Oncol
(2019) - et al.
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial
J Hepatol
(2018) - et al.
Cabozantinib in patients with advanced and progressing hepatocellular carcinoma
N Engl J Med
(2018) - et al.
Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design
Hepatology
(2013) Endpoints for assessing drug activity in clinical trials
Oncologist
(2008)
Cited by (5)
Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function
2022, Digestive and Liver DiseaseCitation Excerpt :However, post-progression survival and treatment crossover can lead to a misinterpretation of OS results [39]. Since post-progression sequential treatments are now available for HCC, radiology-based surrogate endpoints, such as progression-free survival (PFS), time-to-progression (TTP), and objective response rate (ORR), are commonly used as secondary outcomes in phase III trials or primary outcomes in phase II studies [40]. Before a surrogate endpoint can replace OS to assess treatment efficacy in a phase III trial, it must be formally validated at both study and individual levels [38].
Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?
2021, Seminars in Liver Disease